Kit (CD117) positive
2 drugsPredictive biomarker for patient selection in 9 indications
2
Approved Drugs
9
Indications
2
Companies
Kit (CD117) positive is a precision-medicine biomarker linked to 2 FDA-approved targeted drugs from 2 companies, spanning 9 indications including Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic/Myeloproliferative Diseases. Explore the targeted therapies, indications, testing methods, and companies developing Kit (CD117) positive drugs below.
Search Kit (CD117) positive Clinical Trials
Search recruiting trials on ClinicalTrials.gov
Drugs Targeting Kit (CD117) positive
| Drug | Company | Therapeutic Area |
|---|---|---|
| IMATINIB MESYLATE | Viatris | Oncology |
| IMKELDI | SHORLA ONCOLOGY | Oncology |
Kit (CD117) positive Indications
Chronic Myeloid Leukemia Acute Lymphoblastic Leukemia Myelodysplastic/Myeloproliferative Diseases Aggressive Systemic Mastocytosis Hypereosinophilic Syndrome Chronic Eosinophilic Leukemia Dermatofibrosarcoma Protuberans Gastrointestinal Stromal Tumor Gastrointestinal Stromal Tumors